샘플 요청 목록

 카트 문의
시장보고서
상품코드
1761089

세계의 Drug Discovery 기술 시장

Drug Discovery Technologies
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 486 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Drug Discovery 기술 세계 시장은 2030년까지 미국에서 1,242억 달러에 달할 전망

2024년에 754억 달러로 추정되는 Drug Discovery 기술 세계 시장은 분석 기간인 2024-2030년에 CAGR 8.7%로 성장하여 2030년에는 1,242억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 저분자 의약품은 CAGR 8.4%를 기록하며 분석 기간 종료시에는 927억 달러에 달할 것으로 예상됩니다. 생물학적 제제 부문의 성장률은 분석 기간 동안 CAGR 9.6%로 추정됩니다.

미국 시장은 202억 달러로 추정, 중국은 CAGR 10.6%로 성장 예측

미국의 Drug Discovery 기술 시장은 2024년에 202억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 190억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 10.6%가 됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 7.7%와 7.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 8.2%로 성장할 것으로 예측됩니다.

세계의 Drug Discovery 기술 시장 - 주요 동향과 촉진요인 정리

Drug Discovery 기술이란?

Drug Discovery 기술은 신약을 발굴하고 개발하는 데 사용되는 다양한 방법과 도구로 구성되어 있습니다. 이러한 기술은 차세대 의약품이 될 수 있는 새로운 화합물을 발견하고 최적화하는 과정을 간소화하기 때문에 제약 산업에서 매우 중요합니다. 주요 기술로는 하이스루풋 스크리닝(HTS), 유전체학, 유전체학, 단백질체학, 생물정보학, 인공지능(AI) 등이 있으며, HTS를 통해 연구자들은 수백만 개의 화학적, 유전학적, 약리학적 테스트를 신속하게 수행하여 실용적인 의약품으로 이어지는 활성 화합물의 발견을 획기적으로 앞당길 수 있습니다. 활성 화합물의 발견을 획기적으로 앞당길 수 있습니다. 유전체학 및 단백질체학은 질병과 관련된 유전자 및 단백질의 발현에 대한 인사이트를 제공하고 약물 치료의 새로운 표적을 제공합니다.

인공지능은 어떻게 신약개발을 변화시킬까?

인공지능(AI)은 전례 없는 데이터 처리 능력과 예측력을 제공함으로써 신약 개발 프로세스에 혁명을 일으키고 있으며, AI 알고리즘은 의약품 임상시험, 환자 기록, 유전자 정보 등 방대한 데이터세트를 분석하여 기존 방식에 비해 적은 시간과 비용으로 더 높은 정확도로 잠재적인 신약 후보를 식별할 수 있습니다. 더 높은 정확도로 잠재적 의약품 후보물질을 식별할 수 있습니다. 머신러닝 모델은 특히 데이터에서 복잡한 패턴을 인식하고, 서로 다른 화학제품이 인체와 상호 작용하는 방식을 예측하고, 효능을 높이고 부작용을 줄이기 위해 화학적 구조를 수정할 것을 제안하는 데 능숙합니다. 보다 표적화되고 효과적인 치료를 위해 점점 더 중요해질 것입니다.

새로운 Drug Discovery 기술 도입에 있어 어떤 도전과 기회가 존재할까?

신약개발에 있어 첨단 기술의 통합은 효과적인 치료법 개발에 큰 기회를 가져다주지만, 동시에 도전도 가져옵니다. 로봇공학이나 AI 플랫폼과 같은 신기술의 고비용은 소규모 제약사나 연구기관에게는 장벽이 될 수 있습니다. 또한, 이러한 기술로 생성되는 방대한 양의 데이터를 관리하고 분석하기 위해서는 데이터 관리 인프라와 숙련된 인력에 대한 막대한 투자가 필요합니다. 이러한 어려움에도 불구하고, 의약품 개발과 관련된 시간과 비용을 크게 절감할 수 있는 잠재력은 지속적인 투자의 강력한 인센티브가 되고 있습니다. 신흥 시장 역시 이러한 기술의 가치를 인정하고 있으며, 전 세계적으로 채택이 확대되고 있습니다.

Drug Discovery 기술 시장의 성장 원동력은?

Drug Discovery 기술 시장의 성장은 새로운 치료법에 대한 긴급한 수요, 기술 발전, 제약회사 및 정부의 연구개발에 대한 자금 지원 및 투자 증가 등 여러 요인에 의해 이루어지고 있습니다. 전 세계적으로 만성질환과 감염성 질환이 증가함에 따라 효과적인 의약품의 신속하고 효율적인 개발이 요구되고 있습니다. 신약 발견의 능력과 효율성을 높이는 기술의 발전은 이러한 건강 문제에 대응하는 데 있어 매우 중요합니다. 또한, 제약 업계가 유전자 프로파일에 맞춘 정밀의료에 집중하면서 기존 신약개발의 한계를 뛰어넘어 첨단 기술에 대한 수요가 더욱 증가하고 있습니다.

부문

유형(저분자 의약품, 생물학적 제제), 기술(High Throughput Screening, 바이오칩, 바이오인포매틱스, 약물유전체학·약리유전학, 나노기술, 기타 기술), 최종사용자(연구기관, 제약회사, 바이오테크놀러지 기업, 기타 최종사용자)

조사 대상 기업 사례(총 129개사)

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Antares Pharma, Inc.
  • Ambrx, Inc.
  • ActivX Biosciences, Inc.
  • Alembic Pharmaceuticals Limited
  • BioVision, Inc.
  • Acadia Pharmaceuticals, Inc.
  • Beactica Therapeutics AB
  • Atomwise, Inc.
  • BeiGene LTD.
  • ATXA Therapeutics
  • Bayer Pharmaceuticals

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범에 따르는 대신 비디오 트랜스크립트, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 도메인 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

ksm 25.07.07

Global Drug Discovery Technologies Market to Reach US$124.2 Billion by 2030

The global market for Drug Discovery Technologies estimated at US$75.4 Billion in the year 2024, is expected to reach US$124.2 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end of the analysis period. Growth in the Biologics segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$20.2 Billion While China is Forecast to Grow at 10.6% CAGR

The Drug Discovery Technologies market in the U.S. is estimated at US$20.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$19.0 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.2% CAGR.

Global Drug Discovery Technologies Market - Key Trends & Drivers Summarized

What Are Drug Discovery Technologies and How Do They Propel Pharmaceutical Innovation?

Drug discovery technologies comprise a broad range of methods and tools used in the identification and development of new therapeutic drugs. These technologies are critical in the pharmaceutical industry as they streamline the process of discovering and optimizing new compounds that may become the next generation of medications. Key technologies include high-throughput screening (HTS), genomics, proteomics, bioinformatics, and artificial intelligence (AI). HTS allows researchers to quickly conduct millions of chemical, genetic, or pharmacological tests, dramatically speeding up the discovery of active compounds that could lead to viable drugs. Genomics and proteomics provide insights into the genetic and protein expressions related to diseases, offering new targets for drug therapy.

How Is Artificial Intelligence Transforming Drug Discovery?

Artificial intelligence (AI) is revolutionizing the drug discovery process by offering unprecedented data processing capabilities and predictive power. AI algorithms can analyze vast datasets from drug trials, patient records, and genetic information to identify potential drug candidates with higher precision and at a fraction of the time and cost compared to traditional methods. Machine learning models are particularly adept at recognizing complex patterns in data, predicting how different chemicals will interact with the human body, and suggesting modifications to chemical structures to enhance efficacy and reduce side effects. As AI technology continues to evolve, its integration into drug discovery processes is becoming increasingly indispensable, enabling more targeted and effective therapies.

What Challenges and Opportunities Exist in the Adoption of New Drug Discovery Technologies?

While the integration of advanced technologies in drug discovery presents significant opportunities for the development of effective treatments, it also introduces challenges. The high cost of new technologies, such as robotics and AI platforms, can be a barrier for smaller pharmaceutical companies and research institutions. Additionally, managing and analyzing the enormous volumes of data generated by these technologies require substantial investments in data management infrastructure and skilled personnel. Despite these challenges, the potential to drastically reduce the time and cost associated with drug development is a compelling incentive for continued investment. Emerging markets are also recognizing the value of these technologies, leading to increased adoption worldwide.

What Drives the Growth in the Drug Discovery Technologies Market?

The growth in the drug discovery technologies market is driven by several factors, including the urgent need for new medical treatments, advancements in technology, and increased funding and investment in R&D by pharmaceutical companies and governments. The rising prevalence of chronic and infectious diseases worldwide demands faster and more efficient development of effective drugs. Technological advancements that offer enhanced capabilities and efficiencies in discovering new drugs are critical in meeting these health challenges. Additionally, the pharmaceutical industry's focus on precision medicine tailored to genetic profiles is pushing the boundaries of traditional drug discovery, further fueling the demand for advanced technologies.

SCOPE OF STUDY:

The report analyzes the Drug Discovery Technologies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Small Molecule Drugs, Biologics); Technology (High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology, Other Technologies); End-Use (Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 129 Featured) -

  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Antares Pharma, Inc.
  • Ambrx, Inc.
  • ActivX Biosciences, Inc.
  • Alembic Pharmaceuticals Limited
  • BioVision, Inc.
  • Acadia Pharmaceuticals, Inc.
  • Beactica Therapeutics AB
  • Atomwise, Inc.
  • BeiGene LTD.
  • ATXA Therapeutics
  • Bayer Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Drug Discovery Technologies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • A Prelude to Drug Discovery Technologies
    • Global Market Analysis and Prospects
    • Global Drug Discovery Technologies Market Set to Witness Rapid Growth
    • Regional Market Analysis
    • Market Analysis based on Application
    • Market Analysis based on End-User
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Late-Stage Drug Failures Drives Demand for Drug Discovery Technolgies
    • Factors Leading to Failure of Drugs in Phase III Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others
    • Cell-based Assays Play a Critical Role in Drug Discovery
    • Major Types of Cell-Based HTS Assays for Drug Screening
    • High-Content Screening (HCS) - An Expanding Technology in Cell-Based Assays
    • High Content Screening - Key Application Areas
    • Technology Advances in Drug Discovery Processes
    • Increased Demand of Biochips in Drug Discovery to Drive Market Growth
    • Increased Demand for Personalized Medicine to Drive Drug Discovery Technologies Market
    • Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
    • Proteomics and Genomics Drive Opportunities for Drug Discovery Technologies
    • Proteomics Profiling to Expedite Drug Discovery
    • Other Applications of Proteomics in Drug Discovery
    • New Proteomics Technique to Aid Drug Screening & Biomarker Discovery
    • Proteomic Approaches Gain Prominence in Cancer Drug Discovery
    • Proteomics Technologies Used in Cancer Drug Discovery and Development
    • Role of Proteomics in Oncology Biomarker Discovery
    • Bioinformatics Tools along with Proteomics Accelerate the Process of Pathway Prediction
    • Using AI in Drug Discovery: The Latest Market Research
    • High-throughput Screening (HTS) - A Key Drug Discovery Technology
    • HTS: Making Use of a Smarter Approach to Hit Discovery
    • Emerging Technologies in Drug Discovery and Development
    • Targeted Drug Development and Discovery
    • Significance of Advanced Clinical Sequencing for Drug Developers
    • Metabolomics: An Emerging Trend in Drug Discovery
    • Impact of ADME-Tox Screening on New Drug Discovery
    • Phase-I Clinical Trial Failures Before and After the Advent of Preclinical ADME/Pharmacokinetics
    • Pharma Industry Renews Focus on Cost Optimization
    • China and India: Hot Spots for R&D Investment
    • Omics Technology to Witness Rapid Growth
    • Adoption of Omics-based Technologies
    • Increasing Demand for 3D Cell Culture in Drug Discovery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Drug Discovery Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Small Molecule Drugs by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for High Throughput Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for High Throughput Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for High Throughput Screening by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Biochips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Biochips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Biochips by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Pharmacogenomics & Pharmacogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Pharmacogenomics & Pharmacogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Pharmacogenomics & Pharmacogenetics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Nanotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Nanotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Nanotechnology by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 39: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 40: World Drug Discovery Technologies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Drug Discovery Technologies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Drug Discovery Technologies by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Drug Discovery Technologies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Drug Discovery Technologies by Type - Small Molecule Drugs and Biologics Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of World 15-Year Perspective for Drug Discovery Technologies by Type - Percentage Breakdown of Value Revenues for Small Molecule Drugs and Biologics for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of World Historic Review for Drug Discovery Technologies by Technology - High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of World 15-Year Perspective for Drug Discovery Technologies by Technology - Percentage Breakdown of Value Revenues for High Throughput Screening, Biochips, Bioinformatics, Pharmacogenomics & Pharmacogenetics, Nanotechnology and Other Technologies for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Drug Discovery Technologies by End-Use - Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of World 15-Year Perspective for Drug Discovery Technologies by End-Use - Percentage Breakdown of Value Revenues for Research Institutes, Pharmaceutical Companies, Biotechnology Companies and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제